Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of RO6895882 in advanced CEA-positive solid tumors
NL-OMON41678Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2014
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of cergutuzumab amunaleukin in Nonhematologic neoplasms, sponsored by Roche. Primary endpoints: Safety profile, Maximum tolerated dose and 4 more. Started Feb 2014; status: active, not recruiting.
02
Drugs
cergutuzumab amunaleukin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON41678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41678.